Patents Assigned to Dren Bio, Inc.
-
Publication number: 20250230247Abstract: The present disclosure relates to antibodies that bind human Dectin-1, multispecific (e.g., bispecific) binding molecules, and methods of use and production related thereto.Type: ApplicationFiled: April 3, 2023Publication date: July 17, 2025Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Meaghan HAPPER, Xiaodi DENG, Andrew P. AH YOUNG-CHAPON
-
Publication number: 20250223364Abstract: The present disclosure relates to multispecific (e.g., bispecific) binding proteins that bind human Dectin-1 and human CD20, and methods of use and production related thereto.Type: ApplicationFiled: April 3, 2023Publication date: July 10, 2025Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Andrew P. AH YOUNG-CHAPON, Xiaodi DENG, Sridhar VISWANATHAN, Panagiotis FOTAKIS, Ruo Shi SHI
-
Publication number: 20250206826Abstract: The present disclosure relates to a method of depleting or reducing the numbers of disease-causing agents including host cells, or host cells products, microbes or their products in a human subject upon administration of molecule that causes targeted phagocytosis and comprises a binding domain that binds a specific phagocytotic receptor, such as Dectin-1, and a binding domain that binds a specific disease-causing agent. In a specific embodiment, a method of the disclosure depletes or reduces the number of disease-causing agents in tissues, blood, or bone marrow by targeted phagocytosis.Type: ApplicationFiled: December 10, 2024Publication date: June 26, 2025Applicant: Dren Bio, Inc.Inventors: Panagiotis FOTAKIS, Chanty Mariategue CHAN, Ruo Shi SHI, Adam Lewis SALLES, Nenad TOMASEVIC
-
Publication number: 20250197505Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.Type: ApplicationFiled: March 24, 2023Publication date: June 19, 2025Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Ruo Shi SHI, Xiaodi DENG
-
Publication number: 20250197506Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.Type: ApplicationFiled: November 26, 2024Publication date: June 19, 2025Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Ruo Shi SHI
-
Publication number: 20250129168Abstract: The present disclosure relates to antibodies that bind human Dectin-1, multispecific (e.g., bispecific) binding molecules, and methods of use and production related thereto.Type: ApplicationFiled: September 30, 2024Publication date: April 24, 2025Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Meaghan HAPPER, Xiaodi DENG, Andrew P. AH YOUNG-CHAPON
-
Patent number: 12037399Abstract: The present disclosure relates to antibodies that bind human Dectin-1, multispecific (e.g., bispecific) binding molecules, and methods of use and production related thereto.Type: GrantFiled: October 6, 2021Date of Patent: July 16, 2024Assignee: Dren Bio, Inc.Inventors: Panagiotis Fotakis, Andrew P. Ah Young-Chapon, Nenad Tomasevic, Ruo Shi Shi, Xiaodi Deng
-
Patent number: 11795228Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.Type: GrantFiled: September 29, 2021Date of Patent: October 24, 2023Assignee: Dren Bio, Inc.Inventors: Nenad Tomasevic, Ruo Shi Shi
-
Publication number: 20220185895Abstract: The present disclosure relates to methods of treating diseases or disorders associated with LGL and/or NK cells, methods of reducing or depleting LGL and/or NK cells, and methods of inducing ADCC activity using antibodies that bind to a cell surface protein on LGL and/or NK cells and comprise enhanced ADCC activity. The present invention also relates to a method of depleting or reducing the numbers of large granular lymphocytes and natural killer cells in a human subject upon administration of CD94 or CD57 or NKG2A binding molecule that consists of a part that specifically binds to the CD94 or CD57 or NKG2A receptors and an immunoglobulin Fc part. In a specific embodiment, a method of the invention depletes or reduces the number of large granular lymphocytes and natural killer cells in spleen, blood, bone marrow, joints, or other tissues.Type: ApplicationFiled: March 26, 2020Publication date: June 16, 2022Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Ruo Shi SHI, Arun KASHYAP
-
Publication number: 20220169737Abstract: The present disclosure relates to a method of depleting or reducing the numbers of disease-causing agents including host cells, or host cells products, microbes or their products in a human subject upon administration of molecule that causes targeted phagocytosis and comprises a binding domain that binds a specific phagocytotic receptor, such as Dectin-1, and a binding domain that binds a specific disease-causing agent. In a specific embodiment, a method of the disclosure depletes or reduces the number of disease-causing agents in tissues, blood, or bone marrow by targeted phagocytosis.Type: ApplicationFiled: April 3, 2020Publication date: June 2, 2022Applicant: Dren Bio, Inc.Inventors: Panagiotis FOTAKIS, Chanty Mariategue CHAN, Ruo Shi SHI, Adam Lewis SALLES, Nenad TOMASEVIC
-
Publication number: 20220127366Abstract: The present disclosure relates to antibodies that bind human Dectin-1, multispecific (e.g., bispecific) binding molecules, and methods of use and production related thereto.Type: ApplicationFiled: October 6, 2021Publication date: April 28, 2022Applicant: Dren Bio, Inc.Inventors: Panagiotis FOTAKIS, Andrew P. AH YOUNG-CHAPON, Nenad TOMASEVIC, Ruo Shi SHI, Xiaodi DENG
-
Publication number: 20220127365Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.Type: ApplicationFiled: September 29, 2021Publication date: April 28, 2022Applicant: Dren Bio, Inc.Inventors: Nenad TOMASEVIC, Ruo Shi SHI